Terms: = Lung cancer AND BCR, FLJ16453, 613, ENSG00000186716, BCR1, D22S662, D22S11, CML, P11274, PHL, ALL AND Prognosis
66 results:
1. Exploring the molecular and immune-landscape of lung cancer associated with cystic airspaces.
Zheng X; Qiu L; Huang Y; Cheng R; Huang S; Xu K; Cai W; Deng Y; Wang W; Zhong X; Cui F; Hao Z; Liu J
Mol Immunol; 2024 Apr; 168():75-88. PubMed ID: 38430689
[TBL] [Abstract] [Full Text] [Related]
2. Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis.
Shimizu T; Inoue E; Ohkuma R; Kobayashi S; Tsunoda T; Wada S
Front Immunol; 2023; 14():1308381. PubMed ID: 38115995
[TBL] [Abstract] [Full Text] [Related]
3. Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application.
Safa FM; Rasmussen T; Fontan L; Xia M; Melnick A; Wiestner A; Lobelle-Rich P; Burger JA; Mouawad Y; Safah H; Flemington EK; Saba NS
Haematologica; 2024 May; 109(5):1348-1358. PubMed ID: 37767562
[TBL] [Abstract] [Full Text] [Related]
4. Anlotinib exerts an anti-T-cell acute lymphoblastic leukemia effect in vitro and in vivo.
Zhang X; Geng L; Yang L; Wang Y; Zou Z; Zhang Y; Xu H; Lei H; Cao Y; Wu Y; Gu W; Zhou L
Cell Signal; 2023 Oct; 110():110837. PubMed ID: 37544636
[TBL] [Abstract] [Full Text] [Related]
5. [Development and validation of prognostic nomogram for malignant pleural mesothelioma].
Xie XJ; Chen JY; Jiang J; Duan H; Wu Y; Zhang XW; Yang SJ; Zhao W; Shen SS; Wu L; He B; Ding YY; Luo H; Liu SY; Han D
Zhonghua Zhong Liu Za Zhi; 2023 May; 45(5):415-423. PubMed ID: 37188627
[No Abstract] [Full Text] [Related]
6. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell lung cancer in Sweden.
Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
[TBL] [Abstract] [Full Text] [Related]
7. Immune Infiltration in Tumor and Adjacent Non-Neoplastic Regions Codetermines Patient Clinical Outcomes in Early-Stage lung cancer.
Cheng C; Nguyen TT; Tang M; Wang X; Jiang C; Liu Y; Gorlov I; Gorlova O; Iafrate J; Lanuti M; Christiani DC; Amos CI
J Thorac Oncol; 2023 Sep; 18(9):1184-1198. PubMed ID: 37146750
[TBL] [Abstract] [Full Text] [Related]
8. [Prognostic factors for non-small cell lung cancer patients with central nervous system metastasis with positive driver genes].
Li R; Zhang SR; Liu XF; Zhang JW; Zhao JY; Bai P; Zhang XC
Zhonghua Yi Xue Za Zhi; 2023 Apr; 103(16):1202-1209. PubMed ID: 37087403
[No Abstract] [Full Text] [Related]
9. [Mucinous tubular and spindle cell carcinoma of kidney: Clinicopathology and prognosis].
Shen Q; Liu YX; He Q
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):276-282. PubMed ID: 37042138
[TBL] [Abstract] [Full Text] [Related]
10. Incidence and appropriate management of drug-induced interstitial lung disease in Japanese patients with unresectable pancreatic cancer: A multicenter retrospective study.
Miyagahara T; Fujimori N; Ueda K; Takamatsu Y; Matsumoto K; Teramatsu K; Takaoka T; Suehiro Y; Shimokawa Y; Omori K; Niina Y; Tachibana Y; Akashi T; Oono T; Ogawa Y
Asia Pac J Clin Oncol; 2023 Aug; 19(4):533-541. PubMed ID: 36478079
[TBL] [Abstract] [Full Text] [Related]
11. Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade.
Peng J; Zhang J; Zou D; Xiao L; Ma H; Zhang X; Li Y; Han L; Xie B
Front Immunol; 2022; 13():960459. PubMed ID: 36420269
[TBL] [Abstract] [Full Text] [Related]
12. The advanced lung cancer inflammation index is the optimal inflammatory biomarker of overall survival in patients with lung cancer.
Song M; Zhang Q; Song C; Liu T; Zhang X; Ruan G; Tang M; Xie H; Zhang H; Ge Y; Li X; Zhang K; Yang M; Li Q; Liu X; Lin S; Xu Y; Xu H; Wang K; Li W; Shi H
J Cachexia Sarcopenia Muscle; 2022 Oct; 13(5):2504-2514. PubMed ID: 35833264
[TBL] [Abstract] [Full Text] [Related]
13. A novel deep learning prognostic system improves survival predictions for stage III non-small cell lung cancer.
Yang L; Fan X; Qin W; Xu Y; Zou B; Fan B; Wang S; Dong T; Wang L
Cancer Med; 2022 Nov; 11(22):4246-4255. PubMed ID: 35491970
[TBL] [Abstract] [Full Text] [Related]
14. Construction and evaluation of a nomogram for predicting survival in patients with lung cancer.
Ouyang J; Hu Z; Tong J; Yang Y; Wang J; Chen X; Luo T; Yu S; Wang X; Huang S
Aging (Albany NY); 2022 Mar; 14(6):2775-2792. PubMed ID: 35321944
[TBL] [Abstract] [Full Text] [Related]
15. B cell-related gene signature and cancer immunotherapy response.
Lundberg A; Li B; Li R
Br J Cancer; 2022 Apr; 126(6):899-906. PubMed ID: 34921229
[TBL] [Abstract] [Full Text] [Related]
16. cml Chapter.
Snyder D
Cancer Treat Res; 2021; 181():97-114. PubMed ID: 34626357
[TBL] [Abstract] [Full Text] [Related]
17. Proteomic biomarkers of non-small cell lung cancer patients.
Baran K; Brzeziańska-Lasota E
Adv Respir Med; 2021; 89(4):419-426. PubMed ID: 34494245
[TBL] [Abstract] [Full Text] [Related]
18. Chronic myeloid leukaemia after chemoradiotherapy for solid malignancies.
Baysal M; Ulutas G; Gokyer A; Umit E; Atli EI; Kirkizlar O; Gürkan H; Demir AM
Natl Med J India; 2020; 33(6):347-348. PubMed ID: 34341212
[TBL] [Abstract] [Full Text] [Related]
19. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
Front Immunol; 2021; 12():724741. PubMed ID: 34335635
[TBL] [Abstract] [Full Text] [Related]
20. Performance of a Machine Learning Algorithm Using Electronic Health Record Data to Identify and Estimate Survival in a Longitudinal Cohort of Patients With lung cancer.
Yuan Q; Cai T; Hong C; Du M; Johnson BE; Lanuti M; Cai T; Christiani DC
JAMA Netw Open; 2021 Jul; 4(7):e2114723. PubMed ID: 34232304
[TBL] [Abstract] [Full Text] [Related]
[Next]
